Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dalian Wanchun Biotechnology Co., Ltd.
Dalian, Liaoning Sheng, Chinabeyondspringpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developed Plinabulin, a small molecule GEF-H1 agonist for non-small cell lung cancer (Phase 2 completed by Nereus) and chemotherapy-induced neutropenia (Phase 3 trials). Rights now held by BeyondSpring Pharmaceuticals.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Fosun PharmaNereus Inc.BeyondSpring Pharmaceuticals, Inc.
Beyond the preview
Go deeper on Dalian Wanchun Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dalian Wanchun Biotechnology Co., Ltd..